| Date | Time | Source | |
| 03/19/2010 | 4:36PM | BW | Biogen Idec to Present at the Barclays Capital 2010 Global Healthcare Conference
Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Barclays Capital 2010 Global Healthcare Conference will be webcast live, via the internet, on Wednesday, March 24, 2010 at 8:30 a.m. EST. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com... More...>> |
| 03/18/2010 | 4:07PM | DJN | 2nd UPDATE: Roche Sees Big Potential In Experimental Drugs
(Adds detail in second and last paragraphs) By Goran Mijuk Of DOW JONES NEWSWIRES Roche Holding AG (RHHBY) Thursday said it may launch about 10 new drugs over the next few years that could become blockbusters, adding more clout to the Swiss firm's already-large group of medicines that generate more than one billion dollars... More...>> |
| 03/18/2010 | 3:00PM | DJN | UPDATE: Roche Sees Blockbuster Potential In Experimental Drugs
(Adds detail.) By Goran Mijuk Of DOW JONES NEWSWIRES Roche Holding AG (RHHBY) Thursday said it may launch about ten new drugs over the next few years that could become blockbusters, adding more clout to the Swiss firm's already large group of medicines that generate more than one billion dollars in revenue every year... More...>> |
| 03/18/2010 | 1:46PM | DJN | Roche Sees Blockbuster Potential In 10 Experimental Drugs
By Goran Mijuk Of DOW JONES NEWSWIRES Roche Holding AG (RHHBY) Thursday said it may launch up to ten new drugs over the next few years that could become blockbusters, adding more clout to the Swiss firm's already large group of medicines that generate more than one billion dollars in revenue every year. During the company's... More...>> |
| 03/17/2010 | 6:53PM | DJN | Roche CEO Touts Pipeline, Remains Open To More Deals
Roche Holding AG (RHHBY, ROG.VX) Chief Executive Severin Schwan said the integration of its $46.8 billion takeover of Genentech Inc. is "by and large completed," expressed his confidence in the Swiss drug giant's pipeline, and said he remains open to yet more deal-making. His comments came in an interview the day before... More...>> |
| 03/17/2010 | 6:52PM | DJN | Biogen: Now 42 Cases Of Brain Infection In Tysabri Patients
Biogen Idec Inc. (BIIB) disclosed seven more cases of a rare brain infection in multiple sclerosis patients using Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 42 as of last Wednesday. Another patient with the infection has died, bringing the total deaths to nine in patients that... More...>> |
| 03/15/2010 | 11:38AM | DJN | Elan: J&J Has Change-Of-Control Option To Buy Remaining Stake In AIP
Elan Corp. (ELN) said Monday its largest shareholder, Johnson & Johnson (JNJ), has a controlling interest in their Alzheimer's Immunotherapy Program, including a "change-of-control" option to buy the remaining 49.9% stake in AIP at fair market value should Elan be bought. "It has been clear since the original deal... More...>> |
| 03/05/2010 | 1:47PM | BW | Biogen Idec to Present at the Cowen and Company 30th Annual Health Care Conference
Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Cowen and Company 30th Annual Health Care Conference will be webcast live, via the internet, on Wednesday, March 10, 2010 at 8:00 a.m. EST. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com... More...>> |
| 02/18/2010 | 6:47PM | BW | FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously... More...>> |
| 02/18/2010 | 2:00AM | BW | Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today announced that they have restructured the collaboration agreement for the companies’ long-acting, recombinant Factor VIII Fc fusion protein (rFVIIIFc) in hemophilia A patients and the recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia... More...>> |
| 02/16/2010 | 5:35PM | DJN | UPDATE: Biogen: 35 Cases Of Brain Infection In Tysabri Patients
Biogen Idec Inc. (BIIB) disclosed four more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 35. The number of deaths remains at eight with patients that have developed progressive multifocal leukoencephalopathy, or PML... More...>> |
| 02/16/2010 | 4:10PM | DJN | Biogen: 35 Cases Of Brain Infection In Tysabri Patients
Biogen Idec Inc. (BIIB) disclosed four more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 35. The number of deaths stands at eight with patients that have developed progressive multifocal leukoencephalopathy, or PML... More...>> |
| 02/12/2010 | 3:32PM | DJN | UPDATE: Mondobiotech Drug Gets New Hope, But Questions Remain
(Adds information in the eighth paragraph.) By Thomas Gryta and Julia Mengewein Of DOW JONES NEWSWIRES Switzerland's Mondobiotech Holding AG (RARE.EB) received a key lifeline for one of its lead pipeline products from United Therapeutics Corp. (UTHR), which is attempting to expand its reach in treating a form of high blood... More...>> |
| 02/12/2010 | 2:57PM | DJN | Mondobiotech Drug Gets New Hope, But Questions Remain
By Thomas Gryta and Julia Mengewein Of DOW JONES NEWSWIRES Switzerland's Mondobiotech Holding AG (RARE.EB) received a key lifeline for one of its lead pipeline products from United Therapeutics Corp. (UTHR), which is attempting to expand its reach in treating a form of high-blood pressure. The move gives the drug, aviptadil... More...>> |
| 02/09/2010 | 11:50AM | DJN | UPDATE: Biogen 4Q Profit Up 48%; Offers Bright 2010 Forecast
Biogen Idec Inc.'s (BIIB) fourth-quarter earnings rose 48% on strength from its multiple sclerosis franchise and offered a bright outlook for 2010. The Cambridge, Mass., biotech company is making efforts to continue the sales growth of its core MS products, as it suffered from another setback to its pipeline. Meanwhile... More...>> |
| 02/09/2010 | 9:35AM | DJN | Biogen: Heart Drug Data Doesn't Support Continued Development
Biogen Idec Inc. (BIIB) said it believes that data on its midstage experimental heart-failure drug doesn't support its continued development in either oral or intravenous formulations. The company made its statement on Tuesday's earnings conference call and mark the latest pipeline setback for the Cambridge, Mass., biotech... More...>> |
| 02/09/2010 | 8:10AM | DJN | Biogen 4Q Profit Rises 48%; 2010 Forecast Above Street Views
DOW JONES NEWSWIRES Biogen Idec Inc.'s (BIIB) fourth-quarter earnings rose 48%, toppling analysts' forecasts, as sales of its controversial multiple-sclerosis drug Tysabri continued to rise. The biotechnology company also forecast 2010 earnings of above $4.55 on mid-single-digit revenue growth. Analysts surveyed by Thomson... More...>> |
| 02/09/2010 | 7:15AM | BW | Biogen Idec Reports Full Year and Fourth Quarter 2009 Results
Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results. Full Year 2009 Highlights: Total revenues in 2009 were $4.4 billion, an increase of 7% versus 2008. The... More...>> |
| 02/08/2010 | 3:00PM | BW | Multiple Sclerosis Experts Join Biogen Idec’s Research and Development Team
Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that John R. Richert, M.D., will be joining the Company as a Senior Fellow in Neurology Research and Development and Nancy D. Richert, M.D., Ph.D., will be... More...>> |
| 02/08/2010 | 2:57PM | DJN | Activists Increasingly Like Biotechs But With Mixed Results
Biotechnology companies, in a sign of the industry's maturity, are increasingly coming under the microscope of shareholder activists, who want the sector to act more like traditional businesses. In recent years, well-known activists like Carl Icahn and Ralph Whitworth have questioned whether larger biotechs, which tend... More...>> |